0.25
+0.005(+2.04%)
Currency In CAD
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
August 13, 1996
| Name | Title | Pay | Year Born |
| Mr. Cameron L. Groome | President, Chief Executive Officer & Director | 597,422 | N/A |
| Dr. Mark Luscher Ph.D. | Senior Vice President of Scientific Affairs | 300,597 | N/A |
| Mr. Philip Casselli | Senior Vice President of Sales, Business Development & Marketing | 316,728 | N/A |
| Mr. James S. Currie | Chief Financial Officer | 350,279 | N/A |
| Dr. Kenneth Hughes Ph.D. | Chief Operating Officer | 362,447 | N/A |
| Mr. Christopher B. Lobb | Compliance Officer, General Counsel & Secretary | 0 | N/A |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
